secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001193125-23-144146
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Disc Medicine Q1 net loss $22.8M, cash $236.4M; pipeline catalysts on track
---------------------------------------------------------------------------

- Net loss $22.8M in Q1 2023 vs $9.9M in Q1 2022; R&D expenses $20.2M including $10M Mabwell upfront.
- Cash and equivalents $236.4M at March 31, 2023, up from $194.6M; funding expected into 2025.
- Bitopertin Phase 2 BEACON interim data at EHA June 9, 2023; topline from BEACON and AURORA by end 2023.
- DISC-0974 Phase 1b/2 in NDD-CKD and MF anemia; interim data expected by end of 2023.
- In-licensed anti-TMPRSS6 mAbs from Mabwell; Phase 1 trial planned for second half 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000119312523144146/0001193125-23-144146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000119312523144146/d481241d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-144146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer